The role of EORTC QLQ-C15-PAL scores and inflammatory biomarkers in predicting survival in terminally ill patients with cancer
Abstract Background The clinical use of patient-reported outcomes as compared to inflammatory biomarkers for predicting cancer survival remains a challenge in palliative care settings. We evaluated the role of the European Organization for Research and Treatment of Cancer Quality of Life Questionnai...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-08049-3 |
id |
doaj-2c1c9ba5e14f4bb3a8f12965b5a0fb93 |
---|---|
record_format |
Article |
spelling |
doaj-2c1c9ba5e14f4bb3a8f12965b5a0fb932021-03-28T11:44:02ZengBMCBMC Cancer1471-24072021-03-012111810.1186/s12885-021-08049-3The role of EORTC QLQ-C15-PAL scores and inflammatory biomarkers in predicting survival in terminally ill patients with cancerNanako Koyama0Chikako Matsumura1Yoshihiro Shitashimizu2Morito Sako3Hideo Kurosawa4Takehisa Nomura5Yuki Eguchi6Kazuki Ohba7Yoshitaka Yano8Education and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical UniversityEducation and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical UniversityEducation and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical UniversityDepartment of Pharmacy, Tachibana Medical Corporation Higashisumiyoshi-Morimoto HospitalDepartment of Pharmacy, Tachibana Medical Corporation Higashisumiyoshi-Morimoto HospitalDepartment of Pharmacy, Tachibana Medical Corporation Higashisumiyoshi-Morimoto HospitalPalliative Care Unit, Tachibana Medical Corporation Higashisumiyoshi-Morimoto HospitalDepartment of Palliative Care, Tachibana Medical Corporation Higashisumiyoshi-Morimoto HospitalEducation and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical UniversityAbstract Background The clinical use of patient-reported outcomes as compared to inflammatory biomarkers for predicting cancer survival remains a challenge in palliative care settings. We evaluated the role of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative scores (EORTC QLQ-C15-PAL) and the inflammatory biomarkers C-reactive protein (CRP), albumin (Alb), and neutrophil-lymphocyte ratio (NLR) for survival prediction in patients with advanced cancer. Methods This was an observational study in terminally ill patients with cancer hospitalized in a palliative care unit between June 2018 and December 2019. Patients’ data collected at the time of hospitalization were analyzed. Cox regression was performed to examine significant factors influencing survival. A receiver operating characteristic (ROC) analysis was performed to estimate cut-off values for predicting survival within 3 weeks, and a log-rank test was performed to compare survival curves between groups divided by the cut-off values. Results Totally, 130 patients participated in the study. Cox regression suggested that the QLQ-C15-PAL dyspnea and fatigue scores and levels of CRP, Alb, and NLR were significantly associated with survival time, and cut-off values were 66.67, 66.67, 3.0 mg/dL, 2.5 g/dL, and 8.2, respectively. The areas under ROC curves of these variables were 0.6–0.7. There were statistically significant differences in the survival curves between groups categorized using each of these cut-off values (p < .05 for all cases). Conclusion Our findings suggest that the assessment of not only objective indicators for the systemic inflammatory response but also patient-reported outcomes using EORTC QLQ-C15-PAL is beneficial for the prediction of short-term survival in terminally ill patients with cancer.https://doi.org/10.1186/s12885-021-08049-3EORTC QLQ-C15-PALInflammatory biomarkersSurvival predictionTerminally ill cancer patientsPalliative care |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nanako Koyama Chikako Matsumura Yoshihiro Shitashimizu Morito Sako Hideo Kurosawa Takehisa Nomura Yuki Eguchi Kazuki Ohba Yoshitaka Yano |
spellingShingle |
Nanako Koyama Chikako Matsumura Yoshihiro Shitashimizu Morito Sako Hideo Kurosawa Takehisa Nomura Yuki Eguchi Kazuki Ohba Yoshitaka Yano The role of EORTC QLQ-C15-PAL scores and inflammatory biomarkers in predicting survival in terminally ill patients with cancer BMC Cancer EORTC QLQ-C15-PAL Inflammatory biomarkers Survival prediction Terminally ill cancer patients Palliative care |
author_facet |
Nanako Koyama Chikako Matsumura Yoshihiro Shitashimizu Morito Sako Hideo Kurosawa Takehisa Nomura Yuki Eguchi Kazuki Ohba Yoshitaka Yano |
author_sort |
Nanako Koyama |
title |
The role of EORTC QLQ-C15-PAL scores and inflammatory biomarkers in predicting survival in terminally ill patients with cancer |
title_short |
The role of EORTC QLQ-C15-PAL scores and inflammatory biomarkers in predicting survival in terminally ill patients with cancer |
title_full |
The role of EORTC QLQ-C15-PAL scores and inflammatory biomarkers in predicting survival in terminally ill patients with cancer |
title_fullStr |
The role of EORTC QLQ-C15-PAL scores and inflammatory biomarkers in predicting survival in terminally ill patients with cancer |
title_full_unstemmed |
The role of EORTC QLQ-C15-PAL scores and inflammatory biomarkers in predicting survival in terminally ill patients with cancer |
title_sort |
role of eortc qlq-c15-pal scores and inflammatory biomarkers in predicting survival in terminally ill patients with cancer |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2021-03-01 |
description |
Abstract Background The clinical use of patient-reported outcomes as compared to inflammatory biomarkers for predicting cancer survival remains a challenge in palliative care settings. We evaluated the role of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative scores (EORTC QLQ-C15-PAL) and the inflammatory biomarkers C-reactive protein (CRP), albumin (Alb), and neutrophil-lymphocyte ratio (NLR) for survival prediction in patients with advanced cancer. Methods This was an observational study in terminally ill patients with cancer hospitalized in a palliative care unit between June 2018 and December 2019. Patients’ data collected at the time of hospitalization were analyzed. Cox regression was performed to examine significant factors influencing survival. A receiver operating characteristic (ROC) analysis was performed to estimate cut-off values for predicting survival within 3 weeks, and a log-rank test was performed to compare survival curves between groups divided by the cut-off values. Results Totally, 130 patients participated in the study. Cox regression suggested that the QLQ-C15-PAL dyspnea and fatigue scores and levels of CRP, Alb, and NLR were significantly associated with survival time, and cut-off values were 66.67, 66.67, 3.0 mg/dL, 2.5 g/dL, and 8.2, respectively. The areas under ROC curves of these variables were 0.6–0.7. There were statistically significant differences in the survival curves between groups categorized using each of these cut-off values (p < .05 for all cases). Conclusion Our findings suggest that the assessment of not only objective indicators for the systemic inflammatory response but also patient-reported outcomes using EORTC QLQ-C15-PAL is beneficial for the prediction of short-term survival in terminally ill patients with cancer. |
topic |
EORTC QLQ-C15-PAL Inflammatory biomarkers Survival prediction Terminally ill cancer patients Palliative care |
url |
https://doi.org/10.1186/s12885-021-08049-3 |
work_keys_str_mv |
AT nanakokoyama theroleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT chikakomatsumura theroleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT yoshihiroshitashimizu theroleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT moritosako theroleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT hideokurosawa theroleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT takehisanomura theroleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT yukieguchi theroleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT kazukiohba theroleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT yoshitakayano theroleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT nanakokoyama roleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT chikakomatsumura roleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT yoshihiroshitashimizu roleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT moritosako roleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT hideokurosawa roleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT takehisanomura roleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT yukieguchi roleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT kazukiohba roleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer AT yoshitakayano roleofeortcqlqc15palscoresandinflammatorybiomarkersinpredictingsurvivalinterminallyillpatientswithcancer |
_version_ |
1724199590347931648 |